Brief: Percheron Therapeutics Appoints Ambrosini as Interim Board Member During CEO Transition Period
31/08/2026 11:27
BRIEF-Percheron Therapeutics Appoints Ambrosini as Interim Board Member During CEO Transition Period Aug 31 (Reuters) - Percheron Therapeutics Ltd PER.AX:
TRANSITIONAL APPOINTMENT OF EXECUTIVE DIRECTOR
AMBROSINI APPOINTED AS INTERIM BOARD MEMBER DURING CEO TRANSITION PERIOD
Further company coverage: PER.AX
((reuters.briefs@thomsonreuters.com;))
Recent news on Percheron Therapeutics
See all newsBrief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Brief: Percheron Therapeutics Receives Firm Commitments For A$2.3 Million Institutional Placement
Brief: Percheron Therapeutics Appoints Ambrosini as Interim Board Member During CEO Transition Period
Brief: Percheron Therapeutics Says Vanderbilt Health To Conduct Clinical Trial Of Hmbd-002 In Acute Myeloid Leukaemia
Brief: Percheron Therapeutics Says James Garner To Step Down As CEO And Managing Director